The authors reply
We thank Sheng-Wen Niu and colleagues1 for highlighting their intriguing data on the association between pioglitazone use and incident nephrolithiasis in patients with type 2 diabetes in the Taiwanese National Health Insurance Research Database. In their population-based retrospective analysis, pioglitazone users experienced a 26% reduction in kidney stone incidence compared with matched diabetic nonpioglitazone users, and greater risk reduction was observed with higher cumulative pioglitazone exposure.
Source: Kidney International - Category: Urology & Nephrology Authors: Khashayar Sakhaee, Naim Maalouf Tags: Letter to the Editor Source Type: research
More News: Actos | Databases & Libraries | Diabetes | Diabetes Type 2 | Endocrinology | Health Insurance | Insurance | Kidney Stones | Taiwan Health | Urology & Nephrology